<DOC>
	<DOCNO>NCT01510951</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , immunogenicity , clinical effect AMG 811 follow single subcutaneous dose administration subject moderate severe psoriasis .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Pharmacodynamics , Clinical Effects AMG 811 Subjects With Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>18 55 year old inclusive Screening Active clinically stable , plaque psoriasis Psoriasis involve ≥ 10 % body surface area A minimum PASI score ≥ 10 obtained screen period Additional inclusion criterion apply Active guttate , erythrodermic , pustular psoriasis time screen visit Evidence skin condition psoriasis ( eg , eczema ) time screen visit screen visit study drug initiation would interfere evaluation effect investigational product psoriasis Any condition , judgment investigator , might cause study detrimental subject Additional exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>AMGEN</keyword>
	<keyword>PSORIASIS</keyword>
	<keyword>SAFETY</keyword>
</DOC>